N/A N=100 Psychosis: Early Detection, Intervention and Prevention
Prodromal Schizophrenia · Psychotic Disorders · Severe Bipolar Disorder With Psychotic Features
Primary: Onset of Psychosis — 10; 14 percentage of sample converting
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=404 An Integrated Program for the Treatment of First Episode of Psychosis
Schizophrenia · Schizoaffective Disorder · Schizophreniform Disorder
Primary: Mean Heinrichs-Carpenter Quality of Life Scale Scores Over Time — 51.25; 55.13; 59.15; 60.08 score on a scale — p=0.0145
N/A N=103 USS Training to Improve Social Function in People With Psychosis
Psychosis
Primary: Social Functioning Scale (SFS) Change — 1.28; 0.19; 1.56; 0.32 score on a scale
Phase 3 N=57 Aspirin in Young Psychotic Patients
Psychosis · Acute Psychosis · Schizophrenia
Primary: Neurological Soft Signs — 6.96; 7.04 score on a scale — p=0.863
Phase 2 N=63 N-Acetyl-Cysteine (NAC) in Early Phase Schizophrenia Spectrum Psychosis
Schizophrenic Psychoses
Primary: Change in Negative Symptoms of Schizophrenia as Measured on the PANSS — 16.9; 17.2 units on a scale — p=0.50
N/A N=292 Early Detection and Intervention for the Prevention of Psychosis
Schizophrenia · Bipolar Disorder · Depression
Primary: Psychotic Symptoms — 9.2; 6.7 units on a scale — p=.0034
Phase 2 N=51 Ziprasidone in the Psychosis Prodrome
Psychosis Prodrome
Primary: Conversion to Psychosis — 1; 2 participants
Phase 4 N=480 Symptomatic Remission and Social Function in Participants Treated With Paliperidone Extended Release (ER)
Schizophrenia
Primary: Percentage of Participants Achieving Symptomatic Remission by Means of Positive and Negative Syndrome Scale (PANSS) — 11.74 percentage of participants
N/A N=50 Exercise and Markers of Medial Temporal Health in Youth At-risk for Psychosis
Attenuated Psychosis Syndrome
Primary: Brain Volume — 19.8; 54.8; -0.489; -6.28 Change in mm cubed (baseline -followup)
Early Phase 1 N=18 Acceptance and Commitment Therapy for the Inpatient Treatment of Psychosis
Psychotic Disorders
Primary: Brief Psychiatric Rating Scale (Overall & Gorham, 1962) — -8.0; -11.6 percentage of total possible change
N/A N=63 Treatment of Schizophrenia With L-tetrahydropalmatine (l-THP): a Novel Dopamine Antagonist With Anti-inflammatory and Antiprotozoal Activity
Schizophrenia
Primary: Positive and Negative Symptom Improvement — 41.3; 40.3; 36.6; 37.3 score on a scale
Phase 4 N=60 Psychosocial Therapy and Risperidone Treatment in Work Performance in Recent-Onset Schizophrenia
Schizophrenia
Primary: Measurement and Treatment Research to Improve Cognition in Schizophrenia (MATRICS) Consensus Cognitive Battery (MCCB) — 6.7; 0.9; 3.9; 5.9 T scores — p=<0.03
N/A N=14 Interactions of Fronto-Parietal High Frequency rTMS on Anterior Cingulate Cortex Activation in Schizophrenia
Schizophrenia
Primary: Change in BOLD Signal in Anterior Cingulate Cortex — -0.0188; 0.0124 BOLD signal change (Mismatch vs. Match)
N/A N=120 Specialized Treatment Early in Psychosis (STEP)
Schizophrenia and Disorders With Psychotic Features
Primary: Number of Patients Hospitalized — 25; 14 participants — p=0.018
N/A N=77 Psychosis Screening in Juvenile Justice
Psychotic Disorders · Psychosis Nos/Other
Primary: Number of Participants Who Used Outpatient Mental Health Services — 20; 9 Participants — p=.053
Phase 2 N=82 Pharmacologically-augmented Cognitive Therapies (PACTs) for Schizophrenia.
Schizophrenia
Primary: Prepulse Inhibition (PPI) — 22.629; 41.162; 50.626; 50.626 % inhibition of startle
N/A N=8 Clinical Interviews With Detainees With Early Psychosis
First-Episode Psychosis
Primary: Number of Referrals to Correctional Health Services (CHS) — 8 Participants
Phase 2 N=92 Efficacy, Safety, and Tolerability of SPD489 in Adults With Schizophrenia and Predominant Negative Symptoms
Schizophrenia and Predominant Negative Symptoms
Primary: Change From Open-label Baseline in Modified Scale for the Assessment of Negative Symptoms (SANS-18) Total Score at Week 10 Open-label Phase, Last Observation Carried…
N/A N=24 rTMS as a Probe of Episodic Memory Neurocircuitry in Schizophrenia
Schizophrenia
Primary: Change in Precuneus Functional Activation — 0.0329; 0.067; -0.010 Beta coefficient change (Target vs Foil) — p=0.32
N/A N=191 Using Digital Media Advertising to Reduce the Duration of Untreated Psychosis
Schizophrenia · First Episode Psychosis
Primary: Reducing the Duration of Untreated Psychosis — 5.32; 5.38 Days
N/A N=328 An Observational Study On Metabolic Syndrome Parameters In Schizophrenia Patients Treated With Atypical Antipsychotics
Schizophrenia · Metabolic Syndrome X
Primary: Metabolic Syndrome Parameter Body Mass Index (BMI) — 26.3; 26.6; 26.9 kg/m*m (kilograms per meter squared) — p=<0.001
Phase 3 N=228 An Efficacy and Safety Study of Extended-Release (ER) Paliperidone in Adolescent Participants With Schizophrenia
Schizophrenia
Primary: Change From Baseline in the Positive and Negative Syndrome Scale (PANSS) Total Score at Day 56 — 89.6; 92.0; -19.3; -19.8 Units on a scale — p=0.935
Phase 2 N=25 Levetiracetam in Early Psychosis
Psychosis · Schizophrenia · Schizo Affective Disorder
Primary: Change in Cerebral Blood Flow (CBF) — -2.21; -3.83; -1.29 mL / (100g * min)
N/A N=124 Yoga and Aerobic Exercise in Psychosis
Psychotic Disorder
Primary: Verbal Acquisition — 22.8; 22.0; 22.7; 29.5 correctly encoded words — p=<0.01
Phase 4 N=60 Low Dose Amisulpride Vs Olanzapine-Fluoxetine Combination in Post-Schizophrenic Depression
Post-Schizophrenic Depression
Primary: Calgary Depression Scale for Schizophrenia (CDSS) — 8.31; 8.62 score on a scale
N/A N=30 Customized Adherence Enhancement Plus Long-acting Injectable Antipsychotic
Patient Noncompliance
Primary: Change From Baseline in Days Homeless Out of the Previous 6 Months as Measured at 25 Weeks — 6.50; 9.85 days
N/A N=116 Mindfulness, Group Therapy and Psychosis; Training Decreases Anxiety and Depression
Psychosis
Primary: Change in Generalized Anxiety Disorder-7 Pre/Post Test at Week 5 — 4.68; 6.28; 3.96; 7.38 units on a scale — p=0.003
Phase 2 N=44 D-serine for the Schizophrenia Prodrome
Schizophrenia Prodrome
Primary: Scale of Prodromal Symptoms (SOPS) Negative Scale — 7.6; 11.3 SOPS negative final score — p=0.03
Phase 1 N=10 Weight Management Program for Patients With First Episode Psychosis
Diet, Healthy · Psychotic Disorders
Primary: Weight — -6; -3; -5; -4 Lbs
N/A N=66 Artemisinin to Reduce The Symptoms of Schizophrenia
Schizophrenia · Schizoaffective Disorder
Primary: Change in Positive and Negative Syndrome Scale (PANSS) Score From the Beginning to the End of the Double-blind Treatment Phase Weeks 2-12 — 64; 68.13; 61.42; 66.32 units…